Company Profile
Boston Scientific Stock Price, News & Catalysts
- Ticker:
- BSX
- Exchange:
- NYSE
- Sector:
- Biopharma
- Location:
- United States
Stock performance
44.64 USD (-2.58%)
Close
Last updated: November 5, 2026
70.9B USD
Market cap
Why the stock is moving
As of Nov 5, 2026, BSX closed down 2.58% at $44.64. No new same-company headline was identified in the current news window.
Company overview
Global Medical Technology Platform
Boston Scientific is a global medical technology company with products spanning cardiovascular care, endoscopy, urology, neuromodulation, interventional oncology, respiratory care, and gastrointestinal medicine. Its portfolio centers on high-performance devices and minimally invasive therapies designed to improve clinical outcomes while reducing the burden on healthcare systems.
Electrophysiology Franchise
Electrophysiology is a major innovation area for Boston Scientific. The FARAPULSE pulsed field ablation system has demonstrated advantages over antiarrhythmic drug therapy in persistent atrial fibrillation, while the FARAFLEX Mapping and PFA Catheter extends the platform toward integrated cardiac mapping and ablation.
Coronary, Structural Heart, and Embolization
The company also continues to broaden its interventional portfolio. Recent activity includes positive pivotal evidence for the SEISMIQ coronary intravascular lithotripsy catheter, FDA clearance of the TruSelect 2.6 Microcatheter, and strategic exposure to the SIEGEL transcatheter aortic valve replacement system through MiRus.
MedSurg Businesses
Outside cardiovascular care, Boston Scientific’s MedSurg segment provides technologies for endoscopy, urology, neuromodulation, and other minimally invasive procedures. This business mix reduces dependence on any single therapeutic area and gives the company multiple channels for new-product adoption.
Diversified Operating Base
Boston Scientific operates through its Cardiovascular and MedSurg segments, with additional businesses including Urology and Neuromodulation. The company expands its platform through internal R&D, strategic investments, and acquisition options, including its investment in MiRus and potential rights to acquire the SIEGEL TAVR business.
Future catalysts
- Clinical data from the pivotal FARADIGM study of the FARAFLEX mapping and pulsed-field-ablation catheter in 2027.
- Planned launch of the FARAFLEX platform in 2029, subject to successful clinical and regulatory development.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Boston Scientific (BSX)?
Boston Scientific (BSX) most recently closed at 44.64 USD, a -2.58% move versus the previous session.
What is the market cap of Boston Scientific (BSX)?
Boston Scientific currently has a market capitalization of 70.9B USD on BioPharmSignal.
What does Boston Scientific do?
Global Medical Technology Platform Boston Scientific is a global medical technology company with products spanning cardiovascular care, endoscopy, urology, neuromodulation, interventional oncology, respiratory care, and gastrointestinal medicine. Its portfolio centers on high-performance devices and minimally invasive therapies designed to improve clinical...
On which exchange is BSX stock listed?
Boston Scientific (BSX) is associated with NYSE, United States, Biopharma.
What is Global?
Global Medical Technology Platform Boston Scientific is a global medical technology company with products spanning cardiovascular care, endoscopy, urology, neuromodulation, interventional oncology, respiratory care, and gastrointestinal medicine.
Which conditions is Boston Scientific targeting with Global?
Boston Scientific is associated with oncology, cardiovascular disease, respiratory disease based on its company overview and current catalyst commentary.
How does Boston Scientific describe recent progress with Global?
Clinical data from the pivotal FARADIGM study of the FARAFLEX mapping and pulsed-field-ablation catheter in 2027. Planned launch of the FARAFLEX platform in 2029, subject to successful clinical and regulatory development.
What is Medical?
Global Medical Technology Platform Boston Scientific is a global medical technology company with products spanning cardiovascular care, endoscopy, urology, neuromodulation, interventional oncology, respiratory care, and gastrointestinal medicine.